Prasinezumab
Product Specifications
UNSPSC Description
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research[1].
Target Antigen
α-synuclein
Type
Inhibitory Antibodies
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/prasinezumab.html
Purity
99.90
Solubility
10 mM in DMSO
Smiles
[Prasinezumab]
References & Citations
[1]Gennaro Pagano, et al. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. Front Neurol. 2021 Oct 1;12:705407.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99405/Prasinezumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99405/Prasinezumab-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
1960462-19-4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1028486-01 0.02 mg (E-Coli)
Recombinant Shewanella loihica Formamidopyrimidine-DNA glycosylase (mutM)
Ask
View Details 
MBS1028486-02 0.02 mg (Yeast)
Recombinant Shewanella loihica Formamidopyrimidine-DNA glycosylase (mutM)
Ask
View Details MBS1028486-03 0.1 mg (E-Coli)
Recombinant Shewanella loihica Formamidopyrimidine-DNA glycosylase (mutM)
Ask
View Details 
MBS1028486-04 0.1 mg (Yeast)
Recombinant Shewanella loihica Formamidopyrimidine-DNA glycosylase (mutM)
Ask
View Details MBS1028486-05 0.02 mg (Baculovirus)
Recombinant Shewanella loihica Formamidopyrimidine-DNA glycosylase (mutM)
Ask
View Details